Compare TWIN & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWIN | NGNE |
|---|---|---|
| Founded | 1918 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.7M | 327.8M |
| IPO Year | 1994 | 2014 |
| Metric | TWIN | NGNE |
|---|---|---|
| Price | $14.82 | $21.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $12.00 | ★ $60.13 |
| AVG Volume (30 Days) | 44.1K | ★ 156.3K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.53 | N/A |
| Revenue | ★ $340,738,000.00 | $925,000.00 |
| Revenue This Year | $10.79 | N/A |
| Revenue Next Year | $8.43 | N/A |
| P/E Ratio | $9.84 | ★ N/A |
| Revenue Growth | ★ 15.45 | N/A |
| 52 Week Low | $6.16 | $6.88 |
| 52 Week High | $19.63 | $37.27 |
| Indicator | TWIN | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 34.88 | 51.75 |
| Support Level | $14.80 | $19.44 |
| Resistance Level | $14.93 | $21.90 |
| Average True Range (ATR) | 0.82 | 2.35 |
| MACD | -0.35 | 0.07 |
| Stochastic Oscillator | 7.24 | 33.98 |
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.